New White Paper: Data-Driven Drug Selection

Clinical Outcomes in HIV and Psoriasis Through Personalized Pharmacy Review

Download

Free Your Company From a System Designed to Cost You More

VIVIO's open market model and industry-leading clinical team generate savings of 30-50% for self-funded employers. As a Public Benefit Corporation, VIVIO prioritizes what's best for employers and their members, not profits.

Total Drug Management with VIVIO

With programs spanning specialty, non-specialty, and medical drugs, VIVIO is the only partner that manages every category of drug spend. VIVIO leverages data from clinical trials, individual patient information, and market prices - including cash - to deliver the right drug for the right patient at the right price. VIVIO reduces fiduciary risk by ensuring lowest net cost.

No rebate games. No formularies. No out-of-network pharmacies.

Right Drug

Right Patient

Right Price

Right Thing To Do

VIVIO

Analyzes clinical trial data, and independently classifies drugs based on effectiveness.

Personalized Drug Therapies based on the patient's unique medical history.

Open Market to access lower prices wherever they are available.

Employers own their data and meet their fiduciary obligations through unfettered access to VIVIO & Market Data.

Legacy Model

Blindly relies on FDA approvals and guidelines instead of underlying data.

No validation of clinical appropriateness; Prior Authorization auto-approval

"Black Box" drug pricing to limit access and maximize their profit.

Withholds data and exposes employers to Fiduciary risk.

Tailored Drug Therapy for Every Individual

Discover how our innovative approach ensures the right drug for the right person at the right price.

Watch Video

F1000 Public Company Saved $14.8 Million

"Finding, and then hiring VIVIO in 2019 was one of the best decisions I've made in my 44-year career. Our experience as a VIVIO customer prior to and post-launch has been incredibly positive."

-John Steele, Retired, EVP and CFO, Werner Enterprises

%
Program Savings
%
Personalized Therapy Review
%
Member Satisfaction
Download Case Study

VIVIO's Product Suite

Discover VIVIO's technology-driven product suite, designed to enhance drug management with personalized care, transparency, and cost savings. Whether replacing your PBM or improving your current setup, VIVIO offers tailored products to meet your unique needs, delivering exceptional value in healthcare management.

Specialty Carve-Out

Management of self-administered drugs focusing on the right drug, for the right person, at the right price.

40%+ Savings on Specialty Drug Spend

Total Drug Management

 

Full PBM replacement for all prescription drugs leveraging the Cash Pay marketplace.

 

30%+ Savings on Pharmacy Drug Spend

Medical Carve-Out

Medical specialty drug management (HCPCS codes).

50%+ Savings on Medical Specialty Drug Spend

GLP-1 Program (Add-On)

Clinically driven GLP-1 program to manage out of control spend on diabetes.

HIV Program (Add-On)

Clinically driven program to manage out of control spend on HIV (includes PEP and PrEP).

How can VIVIO Help You?

VIVIO's comprehensive drug management offerings provide a commonsense way to achieve significant drug spend savings while improving outcomes. With VIVIO, you can trust that you're providing the best care for your employees while also protecting your organization from legal and compliance risks.

Contact us for a FREE savings analysis to discover how much you or your client can save with VIVIO.

Contact Us

Stay Informed

Dive into our expert webinars, white papers, and comprehensive resources designed to support your decision-making.

View all resources

 

Data-Driven Drug Selection

Clinical Outcomes in HIV and Psoriasis Through Personalized Pharmacy Review: A Discussion on Published VIVIO White Paper

 

Data-Driven Drug Selection

Research

Dive deeper into the topics explored by our team of experts. VIVIO clinicians publish research and articles pertaining to the latest news in healthcare.

ESMO 2024: Highlights and Analysis

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

ecancer, 09/17/2024

Associate Professor Bishal Gyawali of Queen's University talks to ecancer at the 2024 ESMO Congress about his highlights from this year's conference.

Does FDA Withdrawal of Cancer Drug Show Bigger Changes Needed?

Neil Osterweil, Referencing Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

Oncology News Central, 03/12/2024

Although the FDA's accelerated approval policy is designed to help patients get access to promising drugs, some experts remain skeptical about certain aspects of the process. The recent withdrawal of a cancer drug has raised concerns among physicians about patient safety and drug efficacy.

Congressional Investigation of RevAssist-Linked and General Pricing Strategies for Lenalidomide

Kevin Knopf, MD, MBA, Director of Clinical Innovation, VIVIO

JCO Oncology Practice, 02/27/2024

Lenalidomide is an example of a drug whose financial success resulted from price increases and anticompetitive market strategies. We review tactics that led lenalidomide to become the third largest revenue-producing pharmaceutical product worldwide, with $12.2 US dollars (USD) billion sales in 2020, focusing on impact on patients and Medicare and developing policy recommendations.
High costs of drugs are not tightly correlated with value, and pricing decisions by many manufacturers are responsible for high costs, patient burden, and unsustainable pharmaceutical markets.

Perspectives on Cancer Therapy Development

William J.M. Hrushesky, MD, FACP, ABIM IM & MO, VIVIO Clinical Advisory Board

The Asco Post, 09/10/2023

I vividly recall a young veteran with a highly treatable and potentially curable cancer. We quickly reached what seemed a “fork in the road.” Two effective therapies were available: one inexpensive and generic and a second an equally good patented and expensive medicine. There was no evidence of superiority of either.
I informed him of the vast price difference and asked which he would prefer. This veteran did not hesitate for a second: “I will take the cheap one, doc…. I am not the only one in this foxhole.” This sentence broke my heart, and, to this day, its recall gives me goose flesh and unavoidable flowing tears. This intense and unforgettable experience, although long ago and far away, remains highly relevant to today’s cancer medicine.

The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

The New England Journal of Medicine, 09/09/2023

The Food and Drug Administration (FDA) approves about two thirds of new cancer drugs on the basis of clinical trials that use surrogate end points, such as laboratory values or radiographic findings, rather than clinical end points that assess survival or how patients feel or function. The accelerated approval program allows drugs designed to treat serious conditions for which there is an unmet medical need to be approved on the basis of changes in surrogate measures that are only reasonably expected to predict clinical outcomes. Because in certain fields of medicine, such as cancer, a drug’s effects on surrogate measures such as tumor size (see table) are often more pronounced and occur more rapidly than effects on a patient’s clinical status, trials focused on surrogate measures can enroll fewer patients and can be completed more quickly than trials with clinical end points, thereby enabling products to reach the market earlier. Since clinical end points such as survival are generally what matter to patients, however, the FDA requires that the clinical benefits of drugs granted accelerated approval be confirmed in subsequent trials.

Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?

Daniel A. Goldstein, MD and Bishal Gyawali, MD, VIVIO Clinical Advisory Board

Journal of Clinical Oncology, 03/24/2023

The benefit of any treatment for any disease should be judged by whether it improves either survival or its quality. For adjuvant treatment of cancer, effects on overall survival (OS) are paramount: Patients and their oncologists are willing to accept substantial toxicity and short-term deficits in quality of life, if long-term survival can be improved. Assessment of the validity of randomized controlled trials (RCTs) evaluating adjuvant therapy requires that several questions about trial design and analysis be addressed.

Lowering Clinical Trial Standards for the Poor

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

The Lancet, 12/26/2021

An increasing number of cancer clinical trials are conducted in low-and-middle-income countries (LMICs). Increasing the representation of LMICs in cancer drug trials is encouraging, but we are concerned about research parasitism and parachutism in these practices. In this commentary, we explore how LMICs may not have been served by participating in these global cancer drug trials.

Access to Cancer Medicines Deemed Essential by Oncologists in 82 Countries

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

The Lancet, 09/21/2021

The WHO Essential Medicines List (EML) identifies priority medicines on the basis of a rigorous review of their benefits, harms, affordability, availability, and feasibility of delivery. The EML serves as a valuable tool for policy makers of member states to optimize country-level selection of medicines and to ensure access to these drugs in the context of universal health coverage (UHC). The EML can guide the procurement of medicines, favoring competition among treatments with overlapping benefits, and is the basis of the WHO Prequalification Programme and the Medicines Patent Pool.

The Burden of Out-of-Pocket Costs for NSCLC Care

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

MedPage Today, 04/09/2021

The more lung cancer patients had to pay out of pocket for treatment, the less likely they were to adhere to, or continue, therapy, reported researchers, who also found an indication of resulting less-than-ideal survival odds.

"I've done a lot of implementations in my career. VIVIO's was one of the easiest.

- Mike Adams, Vice President, Benefits & HR Systems, Dean Foods

Save Up to 30% on Your Total Drug Spend

Known for delivering excellence in Specialty Drug Management, VIVIO now offers Total Drug Management, allowing clients to completely replace their PBMs. Contact us today to learn more about our programs.

Contact Us